2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone

SKU: N/A 👁️ 7 views 💬 0 inquiries
Product Name: 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone
CAS No.: 32384-65-9

Molecular Formula: C18H42O6Si4
Molecular Weight: 466.86

Physical Properties:
- Appearance: Colorless to pale yellow oily liquid
- Density: ~0.97 g/cm³
- Boiling Point: 417°C
- Flash Point: 171°C
- Specific Optical Rotation: 46.8°

Product Description:
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone is an organosilicon compound serving primarily as a synthetic intermediate for Type 2 diabetes medications such as dapagliflozin and canagliflozin.

Key Features:
- All four hydroxyl groups protected by trimethylsilyl groups
- Used for modification and transformation of glycosyl structures during drug synthesis
- Purity typically ≥ 97%
- Water content controlled below 0.03%

Applications:
- Pharmaceutical intermediate for diabetes medications
- Dapagliflozin synthesis
- Canagliflozin synthesis
- Glycosyl structure modification
- Drug synthesis research

Product Category: Pharmaceutical Intermediates / Organosilicon Compounds / Diabetes Drug Intermediates

Keywords: 32384-65-9, 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone, Dapagliflozin intermediate, Canagliflozin intermediate

Note: For research and development purposes only.

Product Classification:
- Pharmaceutical Intermediates
- Organosilicon Compounds
- Diabetes Drug Intermediates
- Building Blocks
Short Description Organosilicon intermediate for diabetes drug synthesis
MOQ 1 Piece
Contact supplier for shipping and payment information.

📦 Shipping costs are estimated and will be confirmed with the supplier.

💳 Payment terms may vary based on order quantity and buyer history.

📍 Shenzhen, China
📅 Established 2019 (7+ years)
👤 Contact: Liao Huimin
View Company Profile →
Main Products: 2 3 4

More Products from Shenzhen Polymeri Biochemical Technology Co., Ltd.

View All Products →

Send Inquiry for 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone

Fill out the form below and the supplier will respond to you shortly.